# MapLight Therapeutics, Inc.: financial statements, quarterly

MPLT · Nasdaq · CIK 1770069 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mplt.md) · [Financials](/companies/mplt/financials.md) · [Filings](/companies/mplt/filings.md) · [Insiders](/companies/mplt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mplt/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | not reported | not reported | [16.8](/filings/0001193125-25-307453.md) | [20.7 d](/filings/0001193125-26-125072.md) | [19.8](/filings/0001193125-26-224129.md) | [26.8](/filings/0001193125-26-349554.md) | [27.1](/filings/0001193125-25-307453.md) | [64.6 d](/filings/0001193125-26-125072.md) | [53.7](/filings/0001193125-26-224129.md) | [53.4](/filings/0001193125-26-349554.md) |
| Operating income | $m | not reported | not reported | [(20.9)](/filings/0001193125-25-307453.md) | [(22.8) d](/filings/0001193125-26-125072.md) | [(23.5)](/filings/0001193125-26-224129.md) | [(30.7)](/filings/0001193125-26-349554.md) | [(31.5)](/filings/0001193125-25-307453.md) | [(83.4) d](/filings/0001193125-26-125072.md) | [(64.5)](/filings/0001193125-26-224129.md) | [(63.5)](/filings/0001193125-26-349554.md) |
| Net income | $m | [(18.9)](/filings/0001193125-25-307453.md) | [(18.4)](/filings/0001193125-25-307453.md) | [(19.0)](/filings/0001193125-25-307453.md) | [(21.2) d](/filings/0001193125-26-125072.md) | [(22.3)](/filings/0001193125-26-349554.md) | [(29.8)](/filings/0001193125-26-349554.md) | [(29.4)](/filings/0001193125-25-307453.md) | [(79.5) d](/filings/0001193125-26-125072.md) | [(60.7)](/filings/0001193125-26-349554.md) | [(60.2)](/filings/0001193125-26-349554.md) |
| Diluted EPS | $ per share | not reported | not reported | [(25.08)](/filings/0001193125-25-307453.md) | not reported | [(29.33)](/filings/0001193125-26-224129.md) | [(39.11)](/filings/0001193125-26-349554.md) | [(37.18)](/filings/0001193125-25-307453.md) | not reported | [(1.34)](/filings/0001193125-26-224129.md) | [(1.32)](/filings/0001193125-26-349554.md) |
| Basic EPS | $ per share | not reported | not reported | [(25.08)](/filings/0001193125-25-307453.md) | not reported | [(29.33)](/filings/0001193125-26-224129.md) | [(39.11)](/filings/0001193125-26-349554.md) | [(37.18)](/filings/0001193125-25-307453.md) | not reported | [(1.34)](/filings/0001193125-26-224129.md) | [(1.32)](/filings/0001193125-26-349554.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | [38.3](/filings/0001193125-26-125072.md) | not reported | not reported | [64.1](/filings/0001193125-25-307453.md) | [46.7](/filings/0001193125-26-349554.md) | [55.7](/filings/0001193125-26-224129.md) | [71.6](/filings/0001193125-26-349554.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | [115](/filings/0001193125-26-125072.md) | not reported | not reported | [245](/filings/0001193125-25-307453.md) | [325](/filings/0001193125-26-349554.md) | [327](/filings/0001193125-26-224129.md) | [319](/filings/0001193125-26-349554.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | [137](/filings/0001193125-26-125072.md) | not reported | not reported | [257](/filings/0001193125-25-307453.md) | [480](/filings/0001193125-26-349554.md) | [419](/filings/0001193125-26-224129.md) | [368](/filings/0001193125-26-349554.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | [15.9](/filings/0001193125-26-125072.md) | not reported | not reported | [18.6](/filings/0001193125-25-307453.md) | [16.2](/filings/0001193125-26-349554.md) | [14.3](/filings/0001193125-26-224129.md) | [19.3](/filings/0001193125-26-349554.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | [21.7](/filings/0001193125-26-125072.md) | not reported | not reported | [23.7](/filings/0001193125-25-307453.md) | [21.1](/filings/0001193125-26-349554.md) | [19.0](/filings/0001193125-26-224129.md) | [20.0](/filings/0001193125-26-349554.md) |
| Shareholders' equity | $m | [(118)](/filings/0001193125-26-125072.md) | [(136)](/filings/0001193125-25-307453.md) | [(154)](/filings/0001193125-25-307453.md) | [(172)](/filings/0001193125-25-307453.md) | [(194)](/filings/0001193125-26-349554.md) | [(216)](/filings/0001193125-26-349554.md) | [(245)](/filings/0001193125-26-349554.md) | [(274)](/filings/0001193125-25-307453.md) | [458](/filings/0001193125-26-349554.md) | [400](/filings/0001193125-26-349554.md) | [348](/filings/0001193125-26-349554.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(21.5) d](/filings/0001193125-26-125072.md) | [(25.6)](/filings/0001193125-26-224129.md) | [(34.0) d](/filings/0001193125-26-349554.md) | [(31.8) d](/filings/0001193125-25-307453.md) | [(46.8) d](/filings/0001193125-26-125072.md) | [(51.2)](/filings/0001193125-26-224129.md) | [(44.9) d](/filings/0001193125-26-349554.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001193125-26-125072.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-307453.md) | [0.4 d](/filings/0001193125-26-125072.md) | [0.0](/filings/0001193125-26-224129.md) | [0.0 d](/filings/0001193125-26-349554.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.8](/filings/0001193125-25-307453.md) | [0.8](/filings/0001193125-26-224129.md) | [0.8](/filings/0001193125-26-349554.md) | [0.8](/filings/0001193125-25-307453.md) | [45.3](/filings/0001193125-26-224129.md) | [45.4](/filings/0001193125-26-349554.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 42,436,326 at 2026-03-19, from the cover of the [10-K filed 2026-03-26](/filings/0001193125-26-125072.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.